Medicaments (ICS code(s): 11.120.10)

Draft resolution number 1136, 26 December 2022

The Draft resolution number 1136, 26 December 2022, previously notified through G/TBT/N/BRA/1467 - which regards a proposal to define the general guidelines for the pilot implementation of the optimized analysis procedure, based on risk criteria, to confirm the suitability of the documentation submitted to Anvisa for marketing authorization and post-marketing authorization changes to medicines, had its period for comments extended for 60 days by Order number 27, from 06 March 2023.